Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Cash from Operations: 2010-2025

Historic Cash from Operations for Iovance Biotherapeutics (IOVA) over the last 9 years, with Sep 2025 value amounting to -$78.7 million.

  • Iovance Biotherapeutics' Cash from Operations fell 33.45% to -$78.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$323.2 million, marking a year-over-year increase of 11.13%. This contributed to the annual value of -$353.0 million for FY2024, which is 2.44% up from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Cash from Operations of -$78.7 million as of Q3 2025, which was down 16.70% from -$67.4 million recorded in Q2 2025.
  • Iovance Biotherapeutics' Cash from Operations' 5-year high stood at -$59.0 million during Q3 2024, with a 5-year trough of -$122.3 million in Q1 2024.
  • For the 3-year period, Iovance Biotherapeutics' Cash from Operations averaged around -$87.7 million, with its median value being -$84.1 million (2023).
  • Over the last 5 years, Iovance Biotherapeutics' Cash from Operations had its largest YoY gain of 31.48% in 2025, and its largest YoY loss of 33.45% in 2025.
  • Iovance Biotherapeutics' Cash from Operations (Quarterly) stood at -$84.0 million in 2023, then grew by 12.68% to -$73.3 million in 2024, then crashed by 33.45% to -$78.7 million in 2025.
  • Its Cash from Operations was -$78.7 million in Q3 2025, compared to -$67.4 million in Q2 2025 and -$103.7 million in Q1 2025.